Supplementary Table 1. Exposure metrics of ADC and MMAE following intravenous administration of brentuximab vedotin 1.8 mg/kg Q3W (PK subpopulation).

Parameter	Cycle	ADC geometric mean (%CV) (*n* = 24)	Parameter	Cycle	MMAE geometric mean (%CV) (*n* = 23)
C_{max} (µg/mL)	1	27.7 (15.6)	C_{max} (ng/mL)	1	3.19 (23.5)
	4	28.5 (15.3)		4	1.14 (47.9)
T_{max} (hr)[a]	1	0.50 (0.50–0.50)[b]	T_{max} (day)[a]	1	1.95 (28.8)
	4	0.50 (0.50–0.50)[b]		4	1.77 (28.9)
$AUC_{0\text{-}21d}$ (µg*day/mL)	1	66.71 (29.5)	$AUC_{0\text{-}21d}$ (ng*day/mL)	1	20.2 (32.6)
	4	75.85 (28.8)		4	8.44 (52.9)
C_{ave} (µg/mL)	1	3.18 (29.5)	C_{ave} (ng/mL)	1	0.96 (32.6)
	4	3.61 (28.8)		4	0.40 (52.9)
CL (L/day)		0.88 (31.25)	CL_m (L/day)		35.1 (27.3)
$t_{1/2}$ (day)[c]		10.04 (13.24)	$t_{1/2}$ (day)[c]		1.46 (38.9)

%CV, percentage coefficient of variation; ADC, antibody-drug conjugate; $AUC_{0\text{-}21d}$, area under the concentration versus time curve from time 0 to 21 days postinfusion; C_{ave}, average observed concentration; C_{max}, maximum observed concentration; CL, clearance; CL_m, metabolic clearance; MMAE, monomethyl auristatin E; PK, pharmacokinetic; Q3W, every 3 weeks; $t_{1/2}$, half-life; T_{max}, time to C_{max}.

[a]Infusion start and end times were not collected and hence imputed as 30 minutes.

[b]Data presented as median (range).

[c]$t_{1/2}$ reported as model-predicted gamma $t_{1/2}$ for ADC and model-predicted beta $t_{1/2}$ for MMAE.